Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry

Camara, B.; Reymond, Eric D.; Saint-Raymond, Christel; Roth, Hubert; Brenier-Pinchart, Marie-Pierre; Pinel, Claudine; Cadranel, J.; Ferretti, G.; Pelloux, Hervé; Pison, Christophe

doi:10.1111/crj.12105

Cited by 52 publications

(47 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with the findings reported in the literature, the most common host factors predisposing to CPA were previous tuberculosis, COPD, and mild immunodepression [4,8,11,[22][23][24][25]. The potential contribution to the development of CPA of other, less known risk factors was suggested by this case series.…”

Section: Discussionsupporting

confidence: 91%

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA) occur in immunocompetent hosts (3)(4)(5)(6)(7)(8)(9). CPA usually affects patients with underlying lung disease, such as mycobacterial infections, chronic obstructive pulmonary disease (COPD), ABPA, and emphysema (7,9,10).…”

mentioning

confidence: 99%

Prospective Evaluation of a New Aspergillus IgG Enzyme Immunoassay Kit for Diagnosis of Chronic and Allergic Pulmonary Aspergillosis

et al. 2016

View full text Add to dashboard Cite

j Anti-Aspergillus IgG antibodies are important biomarkers for the diagnosis of chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA). We compared the performance of a new commercial enzyme immunoassay (EIA) (Bordier Affinity Products) with that of the Bio-Rad and Virion‫گ‬Serion EIAs. This assay is novel in its association of two recombinant antigens with somatic and metabolic antigens of Aspergillus fumigatus. In a prospective multicenter study, 436 serum samples from 147 patients diagnosed with CPA (136 samples/104 patients) or ABPA (94 samples/43 patients) and from 205 controls (206 samples) were tested. We obtained sensitivities of 97%, 91.7%, and 86.1%, and specificities of 90.3%, 91.3%, and 81.5% for the Bordier, Bio-Rad, and Virion‫گ‬Serion tests, respectively. The Bordier kit was more sensitive than the Bio-Rad kit (P < 0.01), which was itself more sensitive than the Virion‫گ‬Serion kit (P ‫؍‬ 0.04). The Bordier and Bio-Rad kits had similar specificity (P ‫؍‬ 0.8), both higher than that of the Virion‫گ‬Serion kit (P ‫؍‬ 0.02). The area under the receiver operating characteristic (ROC) curves confirmed the superiority of the Bordier kit over the Bio-Rad and the Virion‫گ‬Serion kits (0.977, 0.951, and 0.897, respectively; P < 0.01 for each comparison). In a subset analysis of 279 serum samples tested with the Bordier and Bio-Rad kits and an in-house immunoprecipitin assay (IPD), the Bordier kit had the highest sensitivity (97.7%), but the IPD tended to be more specific (71.2 and 84.7%, respectively; P ‫؍‬ 0.10). The use of recombinant, somatic, and metabolic antigens in a single EIA improved the balance of sensitivity and specificity, resulting in an assay highly suitable for use in the diagnosis of chronic and allergic aspergillosis.

show abstract

“…Sie kann jedoch auch Asthma (Fall 1), zystische Fibrose (CF), ABPA, Pneumothoraces, Lungenkarzinome, Sarkoidose, Bronchiektasie, Pneumokoniosen, Emphysem oder andere präformierte Bullae sowie Lungenentzündungen und thoraxchirurgische Eingriffe verkomplizieren. CPA unter moderater Immunsuppression wie etwa bei Alkoholismus, Diabetes mellitus, chronischer Niereninsuffizienz, Steroidtherapie oder anderer mittelschwer immunsuppressiver Therapie (Fall 4) oder HIV-Patienten vor dem Vollbild AIDS wurden ebenfalls beschrieben (Fall 2) [4,6,9,15,19].…”

Section: Fallunclassified

“…Gewichtsverlust (Fall 3), chronischer z. T. produktiver Husten und Luftnot sind die häufigsten Symptome. Ebenfalls treten Brustschmerzen (Fall 2), Fatigue und Fieber sowie Hämoptysen (Fall 1) auf [4,5,6,9], so dass eine andere konsumierende Erkrankung und insbesondere ein Tumor wichtige Differentialdiagnosen darstellen. Gänzlich asymptomatische Patienten (Fall 4) stellen eher die Ausnahme dar.…”

Section: Klinik Differentialdiagnosen Und Verlauf ▼unclassified

See 1 more Smart Citation

Chronische pulmonale Aspergillose

Schweer

Wittersheim

Bangard

et al. 2014

Dtsch med Wochenschr

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) is a rare complication in patients with either mild immunosuppression or various pulmonary diseases. Diagnosis and therapy are challenging because of unspecific symptoms like productive cough, weight loss, fever and haemoptysis. Differential diagnoses are manifold, and CPA is characterized by findings in chest CT and serologic proof of precipitins. Surgery is only recommended for simple aspergillomas. Recurrent prolonged courses of antifungal treatment yield satisfactory short-term outcome, but long-term prognosis is uncertain. We provide an overview of the literature and present four cases to illustrate disease diversity.

show abstract

Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry

Abstract: Our results provide data on clinical characteristics and outcomes of CPA emphasizing the role of preexisting chronic respiratory conditions and protective effect of preserved BMI and lower Charlson index score.

Cited by 52 publications

References 31 publications

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series

Prospective Evaluation of a New Aspergillus IgG Enzyme Immunoassay Kit for Diagnosis of Chronic and Allergic Pulmonary Aspergillosis

Chronische pulmonale Aspergillose

Contact Info

Product

Resources

About